James Paul

14.2k total citations · 1 hit paper
181 papers, 5.9k citations indexed

About

James Paul is a scholar working on Oncology, Reproductive Medicine and Surgery. According to data from OpenAlex, James Paul has authored 181 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Oncology, 53 papers in Reproductive Medicine and 44 papers in Surgery. Recurrent topics in James Paul's work include Ovarian cancer diagnosis and treatment (52 papers), Colorectal Cancer Treatments and Studies (23 papers) and Cancer Treatment and Pharmacology (19 papers). James Paul is often cited by papers focused on Ovarian cancer diagnosis and treatment (52 papers), Colorectal Cancer Treatments and Studies (23 papers) and Cancer Treatment and Pharmacology (19 papers). James Paul collaborates with scholars based in United Kingdom, United States and Australia. James Paul's co-authors include Robert Brown, John S. Gill, Alex J. Mitchell, David W. Ferguson, Paul Symonds, P. Vasey, Gillian Gifford, Stan B. Kaye, Wallace S. Foulds and Bertil Damato and has published in prestigious journals such as Nature, The Lancet and Journal of Clinical Oncology.

In The Last Decade

James Paul

170 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis

2013 564 citations James Paul et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James Paul United Kingdom	43	2.5k	1.4k	1.3k	1.2k	1.2k	181	5.9k
Noriyuki Katsumata Japan	38	2.8k 1.1×	776 0.6×	1.3k 1.0×	1.2k 1.0×	811 0.7×	183	5.7k
William P. Tew United States	44	3.3k 1.3×	1.1k 0.8×	1.9k 1.5×	1.5k 1.2×	1.6k 1.4×	217	9.3k
Florence Joly France	50	2.8k 1.1×	1.0k 0.7×	1.2k 0.9×	1.0k 0.8×	3.3k 2.8×	330	7.9k
Diana L. Urbauer United States	39	1.5k 0.6×	843 0.6×	807 0.6×	923 0.7×	736 0.6×	150	4.9k
Annette Hasenburg Germany	38	2.3k 0.9×	886 0.7×	1.1k 0.9×	902 0.7×	718 0.6×	260	4.9k
Paul Sabbatini United States	45	4.0k 1.6×	1.8k 1.3×	2.5k 2.0×	1.5k 1.2×	1.9k 1.6×	182	8.8k
Gloria Broadwater United States	42	3.1k 1.2×	1.2k 0.9×	560 0.4×	776 0.6×	1.0k 0.9×	182	6.2k
Lene Mellemkjær Denmark	55	2.6k 1.0×	1.5k 1.1×	595 0.5×	1.9k 1.6×	1.5k 1.3×	209	11.4k
Katia Tonkin Canada	33	4.4k 1.7×	1.8k 1.4×	632 0.5×	700 0.6×	887 0.8×	86	6.5k
Steven Waggoner United States	38	1.8k 0.7×	1.0k 0.8×	1.7k 1.4×	972 0.8×	581 0.5×	136	5.0k

Countries citing papers authored by James Paul

Since Specialization

Citations

This map shows the geographic impact of James Paul's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Paul with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Paul more than expected).

Fields of papers citing papers by James Paul

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Paul. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Paul. The network helps show where James Paul may publish in the future.

Co-authorship network of co-authors of James Paul

This figure shows the co-authorship network connecting the top 25 collaborators of James Paul. A scholar is included among the top collaborators of James Paul based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Paul. James Paul is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Paul, James, Radhakrishnan Govindan, Vijayalakshmi Poreddi, et al.. (2023). An audit of initial six years of 5885 telepsychiatric direct video consultations: Findings from “benefits of savings” analysis and the effect of COVID-19 pandemic. Indian Journal of Psychiatry. 65(6). 611–616.

Sundar, Sudha, Carole Cummins, Joanna Long, et al.. (2021). Quality of life from cytoreductive surgery in advanced ovarian cancer: Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER‐2 cohort study. BJOG An International Journal of Obstetrics & Gynaecology. 129(7). 1122–1132. 19 indexed citations

Wu, Olívia, Elaine McCartney, Robert Heggie, et al.. (2021). Venous access devices for the delivery of long-term chemotherapy: the CAVA three-arm RCT. Health Technology Assessment. 25(47). 1–126. 14 indexed citations

Sundar, Sudha, Sunil Kumar, Junyu Long, et al.. (2020). PATIENT REPORTED OUTCOMES (PRO) AFTER SURGERY IN ADVANCED OVARIAN CANCER - INITIAL RESULTS FROM THE INTERNATIONAL, PROSPECTIVE, MULTICENTER SOCQER 2 STUDY. Queen Mary Research Online (Queen Mary University of London). 1 indexed citations

Roseweir, Antonia K., James H. Park, Sanne ten Hoorn, et al.. (2020). Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer. The Journal of Pathology Clinical Research. 6(4). 283–296. 12 indexed citations

Hesselgreaves, Hannah, Olívia Wu, Jonathan Moss, et al.. (2019). Patient acceptability of three different central venous access devices for the delivery of systemic anticancer therapy: a qualitative study. BMJ Open. 9(7). e026077–e026077. 18 indexed citations

Stronach, Euan A., James Paul, Kirsten M. Timms, et al.. (2018). Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy. Molecular Cancer Research. 16(7). 1103–1111. 81 indexed citations

Paul, James, et al.. (2018). Selected Abstracts from the 2018 NCRI Cancer Conference of National Cancer Research Institute. British Journal of Cancer. 119(S1). 1–49. 3 indexed citations

Hesselgreaves, Hannah, et al.. (2018). Protocol for a systematic review and thematic synthesis of patient experiences of central venous access devices in anti-cancer treatment. Systematic Reviews. 7(1). 61–61. 41 indexed citations

10.

Cooke, Susanna L., Darren Ennis, Lisa Evers, et al.. (2017). The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma. Clinical Cancer Research. 23(24). 7633–7640. 29 indexed citations

11.

Boyd, Kathleen, et al.. (2015). Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer. BMJ Open. 5(10). e007925–e007925. 8 indexed citations

12.

Renfro, Lindsay A., Axel Grothey, James Paul, et al.. (2014). Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. Projecting Analysis Dates for the IDEA Collaboration. SHILAP Revista de lepidopterología. 5(2). 1–7. 1 indexed citations

13.

Glasspool, Rosalind, Robert Brown, Martin Gore, et al.. (2014). A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. British Journal of Cancer. 110(8). 1923–1929. 84 indexed citations

14.

Dai, Wei, Constanze Zeller, Nahal Masrour, et al.. (2013). Promoter CpG Island Methylation of Genes in Key Cancer Pathways Associates with Clinical Outcome in High-Grade Serous Ovarian Cancer. Clinical Cancer Research. 19(20). 5788–5797. 38 indexed citations

15.

Dai, Wei, Jens M. Teodoridis, Constanze Zeller, et al.. (2011). Systematic CpG Islands Methylation Profiling of Genes in the Wnt Pathway in Epithelial Ovarian Cancer Identifies Biomarkers of Progression-Free Survival. Clinical Cancer Research. 17(12). 4052–4062. 78 indexed citations

16.

Johnatty, Sharon E., Jonathan Beesley, James Paul, et al.. (2008). ABCB1 ( MDR 1 ) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy. Clinical Cancer Research. 14(17). 5594–5601. 73 indexed citations

17.

Espie, Colin A., et al.. (2008). Cognitive and attentional changes following cognitive behaviour therapy (CBT) for persistent insomnia associated with cancer: a randomized controlled trial. SLEEP. 31. 1 indexed citations

18.

Jayson, Gordon C., Amanda Gordon, Hani Gabra, et al.. (2004). On behalf of the Scottish Gynaecological Cancer Trials Group. Phase III Randomized Trial of Docetaxel?Carboplatin Versus Paclitaxel?Carboplatin as First-line Chemotherapy for Ovarian Carcinoma. JNCI Journal of the National Cancer Institute. 1682–1691. 100 indexed citations

19.

Vasey, P., Lynn McMahon, James Paul, Nicholas Reed, & Stan B. Kaye. (2003). A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer. British Journal of Cancer. 89(10). 1843–1848. 22 indexed citations

20.

O'Neill, V J, S.B. Kaye, Nicholas Reed, et al.. (2002). A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer. British Journal of Cancer. 86(9). 1385–1390. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact